Skip to main content

Rheumatoid Arthritis

Best of
The last day was jammed with important reports and research including the late breaking abstracts.    What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI…
tumeric
Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR Convergence 2022 suggests that even in…
RT @RichardPAConway: Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commeric

Richard Conway RichardPAConway

3 weeks 1 day ago
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
RT @drdavidliew: Which is better for CV risk in RA:
triple therapy DMARDs or TNFi?

TARGET study
n=159 using PET/CT sur

David Liew drdavidliew

3 weeks 1 day ago
Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsiveness👀) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
RT @RichardPAConway: Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR

Richard Conway RichardPAConway

3 weeks 1 day ago
Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR 1.34, any infection aHR 1.18, hospitalisation aHR 1.34 (all relative non-frail). @RheumNow #ACR22 Abstr#2218 https://t.co/ONsTBq8ehB https://t.co/iTVANh5flk
RT @AurelieRheumo: 💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks

Insom

Aurelie Najm AurelieRheumo

3 weeks 1 day ago
💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insomnia Severity Index -9.8 RAID -1.4 PGA -13 Small sample size wk6 trend improvement sleep efficiency 89% vs84% p=0.07 but not wk26https://t.co/rpKdtbREYs Abs#2188 #ACR22 @RheumNow https://t.co/kEBcPAdIKW
RT @synovialjoints: Peresolimab humanized IgG1 mab
➢ stimulates PD-1 & physiological immune inhibitory pathways
âž

Dr. Antoni Chan synovialjoints

3 weeks 1 day ago
Peresolimab humanized IgG1 mab ➢ stimulates PD-1 & physiological immune inhibitory pathways ➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI ➢ safety events were similar between treatment groups Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, J

Dr. John Cush RheumNow

3 weeks 1 day ago
Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22https://t.co/hIH4WghLwN https://t.co/oKQbBnMiqQ
×